To earn CME related to this news article, click here. February 25, 2009 — A new joint guideline produced by the American Society of Clinical Oncology (ASCO) and the American Urological Association ...
Show More From the Division of Urology, Washington University School of Medicine, St. Louis, MO. Prostate cancer remains a significant public health problem. The current approach with ...
Data on whether 5-ARIs increase the risk of prostate cancer-specific mortality have been mixed. Use of 5-alpha-reductase inhibitors (5-ARIs) does not increase the risk of dying from prostate cancer, ...
A new study suggests that certain drugs commonly used to treat enlarged prostate may also decrease the risk for dementia with Lewy bodies (DLB). This observational finding may seem surprising, but it ...
Long-term use of 5-alpha reductase inhibitors (5-ARIs), used off-label for androgenetic or frontal fibrosing alopecia (FFA) in women, was not associated with an increased risk for osteoporosis or ...
Prostate cancer remains a significant public health problem. The current approach with prostate-specific antigen (PSA)-based screening has questionable effects on prostate cancer–specific mortality ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results